These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18926335)

  • 21. Cumulative antiplatelet effect of low-dose enteric coated aspirin.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Deykin D
    Br J Haematol; 1985 Aug; 60(4):635-42. PubMed ID: 3927970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of various doses of aspirin (in vivo) on platelet arachidonic acid metabolism (ex vivo) and function.
    Rao GH; White JG
    Prostaglandins Leukot Essent Fatty Acids; 1994 Jul; 51(1):63-7. PubMed ID: 7938101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men.
    Jimenez AH; Stubbs ME; Tofler GH; Winther K; Williams GH; Muller JE
    Am J Cardiol; 1992 Jan; 69(3):258-62. PubMed ID: 1731469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
    Bode-Böger SM; Böger RH; Schubert M; Frölich JC
    Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose effect of enteric-coated aspirin on platelet function and thromboxane generation in middle-aged men.
    Mohri H; Ohkubo T
    Ann Pharmacother; 1993 Apr; 27(4):405-10. PubMed ID: 8477113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
    Haastrup P; Jarbøl DE
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
    Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
    Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human platelet response to three salicylate dosage forms.
    Thiessen JJ; Grad H; Macleod SM; Spino M
    Biopharm Drug Dispos; 1983; 4(1):43-51. PubMed ID: 6839001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose enteric-coated aspirin as an antiplatelet preparation.
    McLeod LJ; Roberts MS; Seville PR
    Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
    [No Abstract]   [Full Text] [Related]  

  • 31. Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets.
    Lui CY; Oberle R; Fleisher D; Amidon GL
    J Pharm Sci; 1986 May; 75(5):469-74. PubMed ID: 3735085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin resistance transient laboratory finding or important clinical entity?
    Lev EI
    J Am Coll Cardiol; 2009 Feb; 53(8):678-80. PubMed ID: 19232900
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time.
    Gantt AJ; Gantt S
    Cathet Cardiovasc Diagn; 1998 Dec; 45(4):396-9. PubMed ID: 9863744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin resistance.
    Tantry US; Mahla E; Gurbel PA
    Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
    [No Abstract]   [Full Text] [Related]  

  • 35. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
    Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
    Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(3):263-76. PubMed ID: 8603
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of an enteric coated aspirin preparation.
    Day RO; Paull PD; Champion GD; Graham GG
    Aust N Z J Med; 1976 Feb; 6(1):45-50. PubMed ID: 1065299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of aspirin dosage and enteric coating on platelet reactivity.
    Feng D; McKenna C; Murillo J; Mittleman MA; Gebara OC; Lipinska I; Muller JE; Tofler GH
    Am J Cardiol; 1997 Jul; 80(2):189-93. PubMed ID: 9230157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers.
    Dharmasaroja PA; Sae-Lim S
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):649-52. PubMed ID: 20689403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers.
    Karha J; Rajagopal V; Kottke-Marchant K; Bhatt DL
    Am Heart J; 2006 May; 151(5):976.e7-11. PubMed ID: 16644316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.